NCT05684705View on ClinicalTrials.gov

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

December 30, 2024

Conditions
Bacterial Infections
Interventions
DRUG

BV100

Intravenous infusion

Trial Locations (1)

A-1090

Medical University of Vienna, Vienna

Sponsors

Lead Sponsor

BioVersys AG
All Listed Sponsors
collaborator

CW-Research and Management GmbH

UNKNOWN

lead

BioVersys AG

INDUSTRY

NCT05684705 - Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 | Biotech Hunter | Biotech Hunter